Reassessing the OX40 / OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development program
Journal of the European Academy of Dermatology and Venereology · 2026-08 · 40 (8) · 1286-1287
DOI: 10.1111/jdv.70460 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 31.07.2026. Verfasst von Thomas Bieber. Beteiligte Einrichtung: Department of Dermatology and Allergy, Ludwig-Maximilian University of Munich, Munich, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Dermatology and Allergy, Ludwig-Maximilian University of Munich, Munich, Germany.
- Christine Kühne-Center for Allergy Research and Education, Medicine Campus Davos, Davos, Switzerland.
- Bieber Dermatology Consulting, Feldafing, Germany.
ORCID-Profile: Thomas Bieber
Zitieren
APA
Bieber, T. (2026). Reassessing the OX40 / OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development program. Journal of the European Academy of Dermatology and Venereology, 40(8), 1286-1287. https://doi.org/10.1111/jdv.70460
Vancouver
Bieber T. Reassessing the OX40 / OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development program. Journal of the European Academy of Dermatology and Venereology. 2026;40(8):1286-1287. doi:10.1111/jdv.70460
BibTeX
@article{Bieber2026,
author = {Bieber, Thomas},
title = {Reassessing the OX40 / OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development program},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
volume = {40},
number = {8},
pages = {1286--1287},
doi = {10.1111/jdv.70460}
}
EUVIMED